🇺🇸 FDA
Patent

US 7282206

Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains

granted A61KA61K38/00A61P

Quick answer

US patent 7282206 (Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 16 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K38/00, A61P, A61P1/00, A61P1/16